Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 31, Number 12—December 2025

Synopsis

Retrospective Multicenter Study of Human Granulocytic Anaplasmosis, France, 2012–2024

Victor GerberComments to Author , Thomas Lemmet, Thomas Bonijoly, Baptiste Hoellinger, Anne Pachart, Amandine Woerly, Dominique De Briel, Emilie Talagrand-Reboul, Martin Martinot, Pierre Boyer, and Yves Hansmann
Author affiliation: Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France (V. Gerber, T. Lemmet, B. Hoellinger, A. Woerly, E. Talagrand-Reboul, P. Boyer, Y. Hansmann); Hôpitaux Civils de Colmar, Colmar, France (V. Gerber, T. Lemmet, A. Pachart, D. De Briel, M. Martinot); Centre National de Référence des Borrelia, Strasbourg (V. Gerber, E. Talagrand-Reboul, P. Boyer, Y. Hansmann); Université de Strasbourg, Strasbourg (V. Gerber, E. Talagrand-Reboul, P. Boyer, Y. Hansmann); Centre Hospitalier de Sélestat, Sélestat, France (T. Bonijoly); Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, Mulhouse, France (B. Hoellinger)

Main Article

Table 4

Characteristics and outcomes for 39 cases in a retrospective multicenter study of human granulocytic anaplasmosis, France, 2012–2024*

Patient characteristics HGA episodes
Median delay between symptom onset and diagnosis, d (range)
 8.5 (2–26)
No. hospitalized 34 (87.2)
Median hospitalization duration, d (range) 6 (1–13)
Intensive care unit admission
 0
Antimicrobial treatment
Ineffective therapy before doxycycline 13 (33.3)
No effective antibiotic therapy 10 (25.6)
Treatment with doxycycline 29 (74.4)
Median duration, d (range)
 7 (1–16)
Outcomes
Death <30 d after diagnosis 0
Recovered 39 (100)
Sequelae at 3 mo after diagnosis† 3 (7.7)

*Values are no. (%) except as indicated. HGA, human granulocytic anaplasmosis. †Including asthenia.

Main Article

Page created: December 04, 2025
Page updated: December 15, 2025
Page reviewed: December 15, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external